Breaking News Instant updates and real-time market news.

BIIB

Biogen

$275.41

-2.46 (-0.89%)

, SRPT

Sarepta

$29.68

-0.51 (-1.69%)

04:55
03/24/17
03/24
04:55
03/24/17
04:55

Muscular Dystrophy Association to hold a conference

2017 MDA Scientific Conference is being held in Arlington, VA on March 19-22.

BIIB

Biogen

$275.41

-2.46 (-0.89%)

SRPT

Sarepta

$29.68

-0.51 (-1.69%)

FOLD

Amicus

$7.14

0.07 (0.99%)

CATB

Catabasis Pharmaceuticals

$1.32

-0.085 (-6.05%)

BIIB Biogen
$275.41

-2.46 (-0.89%)

03/17/17
GSCO
03/17/17
NO CHANGE
Target $108
GSCO
Buy
AveXis price target raised to $108 on higher confidence in AVXS-101 at Goldman
After AveXis (AVXS) reported results for its Phase 1 study of AVXS-101 in spinal muscular atrophy, Goldman Sachs analyst Salveen Richter said data for the treatment continues to impress and increased his probability of success for the drug to 85% from 65% previously. The analyst, who views AVXS-101 as a key competitive threat to Biogen (BIIB) and Ionis' (IONS) Spinraza as the potential first-line treatment for SMA, raised his price target on AveXis to $108 from $91 and keeps a Buy rating on the shares.
03/21/17
GSCO
03/21/17
NO CHANGE
Target $282
GSCO
Neutral
Biogen IPR win removes worst-case scenario for Tecfidera, says Goldman
Goldman Sachs analyst Terence Flynn said the USPTO's favorable decision in Kyle Bass' patent challenge to Biogen's Tecfidera removes a worst-case scenario, but notes there is still an outstanding interference proceeding between the company and competitor Forward Pharma regarding the MS drug. Flynn, who projects Tecfidera maintains U.S. exclusivity until 2028 while assuming that Biogen will pays a 10% royalty to Forward Pharma, keeps a Neutral rating and $282 price target on Biogen shares.
03/21/17
RAJA
03/21/17
NO CHANGE
RAJA
Strong Buy
Biogen patent ruling worth $13-$25 per share, says Raymond James
Most investors were expecting a loss for Biogen in today's s Tecfidera patent ruling, Raymond James analyst Christopher Raymond tells investors in an intraday research note. Today's decision means Tecfidera's exclusivity stretches to at least 2025 and possibly to 2028, which the analyst pegs at being worth $13-$25 per share. He recommends buying the stock "before the market figures this out." Raymond has a Strong Buy rating on Biogen. The stock is up $4.16 to $278.96 in midday trading.
03/21/17
JEFF
03/21/17
NO CHANGE
Target $289
JEFF
Buy
Jefferies views Biogen patent ruling as in-line with expectations
Jefferies analyst Brian Abrahams believed with a 70% likelihood that Biogen would prevail in the inter partes review against Hayman Capital's Kyle Bass. Thus, he views patent decision as in-line with expectations. Raymond James analyst Christopher Raymond, on the other hand, said in an intraday research note that he believes most investors were expecting Biogen to lose the patent case. Abrahams thinks the outcome today is a de-risking event for Biogen and removes one of the two possibilities of an unlikely worst-case scenario, with the other being that both patents are debunked in the interference. The analyst has Hold rating on Biogen with a $289 price target.
SRPT Sarepta
$29.68

-0.51 (-1.69%)

03/02/17
03/02/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exxon Mobil (XOM) upgraded to Neutral from Underperform at Credit Suisse with analyst Edward Westlake saying that after underperformance versus the S&P, the stock has option value. The analyst also raised his price target on the shares to $83 from $78. 2. RBS (RBS) upgraded to Buy from Hold at Berenberg. 3. Windstream (WIN) upgraded to Hold from Underperform at Jefferies with analyst Scott Goldman saying he sees less risk to estimates following management's 2017 guidance. The analyst upped his price target for the shares to $7.50 from $6. 4. Sarepta (SRPT) upgraded to Outperform from Market Perform at Leerink with analyst Joseph Schwartz saying the stock now reflects "reasonable expectations" for the Exondys launch. Management's new revenue guidance looks "highly conservative," Schwartz tells investors in a research note. The analyst believes share upside could come from Exondys 51 approval in Europe and/or successful development of follow-on antisense candidates. He raised his price target for Sarepta shares to $47 from $27. 5. Estee Lauder (EL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Stephanie Wissink saying the growth is de-risked following the guidance reset. The analyst is "bullish" on the prospects for double digit earnings growth for investors that can look into FY18. She raised her price target for the shares to $95 from $81. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/10/17
COWN
03/10/17
NO CHANGE
Target $62
COWN
Outperform
Cowen sees coverage re-evaluations as positive for Sarepta
Cowen analyst Ritu Baral believes payors are still actively evaluating and re-evaluating coverage of Sarepta Therapeutics' Exondys 51. It appears that Anthem (ANTM), after an initial denial of coverage, has re-evaluated its decision on Exondys, Baral tells investors in a research note. She notes, though, that coverage discussions appear to be ongoing and amenable patients are still experiencing denials. The analyst sees the re-evaluations of coverage as positive for Sarepta. Baral has an Outperform rating on the shares with a $62 price target.
03/10/17
JPMS
03/10/17
NO CHANGE
Target $42
JPMS
Overweight
JPMorgan raises Sarepta price target after payers survey
JPMorgan analyst Anupam Rama raised his price target for Sarepta Therapeutics to $42 from $40 after conducting a "quick" survey of U.S. based payers. The stock closed yesterday down 70c to $32.73. The results indicate broad and early coverage of Sarepta's Duchene Muscular Dystrophy treatment Exondys 51, Rama tells investors in a research note. Further, the survey shows rapid time from patient start form submission to authorized drug reimbursement, and a steady increase in patient adds over the next 12 months, the analyst adds. The results also made clear, however, that increased disease education is needed at the payer level. The analyst is "very encouraged" by the survey results and increased his 2017 Exondys 51 sales estimate to $94M, above the $90M-$91M consensus. He reiterates an Overweight rating on Sarepta.
03/02/17
LEER
03/02/17
UPGRADE
Target $47
LEER
Outperform
Leerink upgrades Sarepta to Outperform with $47 price target
Leerink analyst Joseph Schwartz upgraded Sarepta Therapeutics to Outperform from Market Perform saying the stock now reflects "reasonable expectations" for the Exondys launch. Management's new revenue guidance looks "highly conservative," Schwartz tells investors in a research note. The analyst believes share upside could come from Exondys 51 approval in Europe and/or successful development of follow-on antisense candidates. He raised his price target for Sarepta shares to $47 from $27. The stock closed yesterday down 73c to $30.38.
FOLD Amicus
$7.14

0.07 (0.99%)

11/29/16
COWN
11/29/16
NO CHANGE
Target $12
COWN
Outperform
Amicus price target lowered to $12 from $15 at Cowen
Cowen analyst Ritu Baral lowered her price target on Amicus to $12 from $15 after the FDA told the company it could not file the Galafold NDA with current data and that data from a new trial is expected in 2019. Baral maintained her Outperform rating on Amicus, stating that the planned GI trial has a good chance of success.
01/24/17
BARD
01/24/17
UPGRADE
BARD
Outperform
Amicus upgraded to Outperform from Neutral at Baird
01/24/17
01/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tableau (DATA) upgraded to Buy from Neutral at Citi with analyst Walter Pritchard saying consensus estimates for fiscal 2017 look low. Revenue transition impacted numbers more than the Street realized in 2016, Pritchard tells investors in a research note. The analyst raised his price target for the shares to $64 from $50. 2. Agrium (AGU) upgraded to Outperform from Market Perform at Cowen, while CF Industries (CF), Mosaic (MOS), and Potash (POT) were upgraded to Market Perform from Underperform. 3. Calithera Biosciences (CALA) upgraded to Neutral from Sell at Citi with analyst Robyn Karnauskas citing her conversation with management. Management now appears more open to partnering, Karnauskas tells investors in a research note. 4. Home Bancshares (HOMB) upgraded to Buy from Hold at Sandler O'Neill. 5. Amicus (FOLD) upgraded to Outperform from Neutral at Baird with analyst Michael Ulz saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. Ulz raised his price target to $10 from $7 on Amicus shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/24/17
BARD
01/24/17
UPGRADE
Target $10
BARD
Outperform
Amicus upgraded to Outperform at Baird
As reported previously, Baird analyst Michael Ulz upgraded Amicus to Outperform from Neutral saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. The analyst believes the launch of Galafold by itself supports the company's current valuation and he sees multiple opportunities for upside from its pipeline. Ulz raised his price target to $10 from $7 on Amicus shares.
CATB Catabasis Pharmaceuticals
$1.32

-0.085 (-6.05%)

03/17/17
OPCO
03/17/17
NO CHANGE
Target $11
OPCO
Outperform
Oppenheimer remains bullish on Catabasis Pharmaceuticals
Oppenheimer analyst Hartaj Singh remains bullish on Catabasis Pharmaceuticals after quarterly results. The analyst notes that the company is hvaing an eventful 2017 with edasalonexent not meeting its primary and secondary endpoints in Part B of the MoveDMD clinical trial. However, a potential efficacy signal was noted and the focus on the earnings call was Part C of the MoveDMD trial, he argues, adding that he is "cautiously optimistic" that long-term treatment in Part C may show enough of an efficacy signal for the drug to move forward into further clinical trials. Singh reiterates an Outperform rating and $11 price target on the shares.
02/01/17
OPCO
02/01/17
NO CHANGE
Target $11
OPCO
Outperform
Catabasis Pharmaceuticals price target lowered to $11 from $18 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Catabasis Pharmaceuticals to $11 from $18 after the company announced that Part B of the MoveDMD clinical trial in Duchenne muscular dystrophy did not meet its primary endpoint. The analyst reiterates an Outperform rating on the shares.
02/01/17
COWN
02/01/17
DOWNGRADE
Target $4
COWN
Market Perform
Catabasis Pharmaceuticals downgraded to Market Perform from Outperform at Cowen
Cowen analyst Phil Nadeau downgraded Catabasis Pharmaceuticals to Market Perform from Outperform following the failed trial for its lead candidate for Duchenne muscular dystrophy. It missed its primary endpoint and showed some signs of activity on secondary endpoints, but they were not strong enough to provide confidence the agent could be successfully developed, said Nadeau, who lowered his price target to $4 from $30 on Catabasis shares.
02/01/17
SBSH
02/01/17
DOWNGRADE
Target $1.5
SBSH
Neutral
Catabasis Pharmaceuticals downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Catabasis Pharmaceuticals to Neutral and cut his price target for the shares to $1.50 from $8 following the company's failed Duchenne muscular dystrophy trial.

TODAY'S FREE FLY STORIES

EEI

Ecology & Environment

$9.90

-0.1 (-1.00%)

18:19
03/27/17
03/27
18:19
03/27/17
18:19
Hot Stocks
Ecology & Environment board urges shareholders to vote for company's nominees »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDLI

PDL BioPharma

$2.05

0.07 (3.54%)

18:16
03/27/17
03/27
18:16
03/27/17
18:16
Hot Stocks
PDL BioPharma CFO discloses purchase of 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:15
03/27/17
03/27
18:15
03/27/17
18:15
General news
Breaking General news story  »

Dallas Federal Reserve…

RAVN

Raven

$29.75

0.45 (1.54%)

18:14
03/27/17
03/27
18:14
03/27/17
18:14
Hot Stocks
Raven CEO says 'entering fiscal year 2018 from a position of strength' »

"We are very pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

RAVN

Raven

$29.75

0.45 (1.54%)

18:12
03/27/17
03/27
18:12
03/27/17
18:12
Hot Stocks
Breaking Hot Stocks news story on Raven »

Raven sees FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

RAVN

Raven

$29.75

0.45 (1.54%)

18:11
03/27/17
03/27
18:11
03/27/17
18:11
Earnings
Raven reports Q4 EPS 12c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

OREX

Orexigen

$4.13

0.15 (3.77%)

18:05
03/27/17
03/27
18:05
03/27/17
18:05
Hot Stocks
Orexigen, Bruno reach distribution agreement for Mysimba »

Orexigen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

HUN

Huntsman

$22.89

0.24 (1.06%)

18:01
03/27/17
03/27
18:01
03/27/17
18:01
Hot Stocks
Huntsman moves up after projecting Q1 adjusted EBITDA to rise YoY »

Shares of chemical maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PFE

Pfizer

$34.18

0.18 (0.53%)

, BMY

Bristol-Myers

$56.04

0.15 (0.27%)

18:00
03/27/17
03/27
18:00
03/27/17
18:00
Hot Stocks
Credit Suisse analysis shows value in hypothetical Pfizer-Bristol merger »

Credit Suisse analysts…

PFE

Pfizer

$34.18

0.18 (0.53%)

BMY

Bristol-Myers

$56.04

0.15 (0.27%)

NVS

Novartis

$75.10

0.73 (0.98%)

GILD

Gilead

$67.50

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 06

    Jun

  • 26

    Jun

  • 27

    Aug

VRX

Valeant

$10.81

0.06 (0.56%)

18:00
03/27/17
03/27
18:00
03/27/17
18:00
Periodicals
Ex-Valeant CEO Pearson sues company over unpaid compensation, WSJ says »

Former Valeant CEO Mike…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

DGLY

Digital Ally

$4.60

0.49 (11.92%)

, TASR

Taser

$22.47

-0.03 (-0.13%)

17:54
03/27/17
03/27
17:54
03/27/17
17:54
Earnings
Digital Ally reports Q4 adjusted EPS (63c), two estimates (20c) »

Reports Q4 revenue…

DGLY

Digital Ally

$4.60

0.49 (11.92%)

TASR

Taser

$22.47

-0.03 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

AEM

Agnico Eagle

$44.64

0.81 (1.85%)

17:51
03/27/17
03/27
17:51
03/27/17
17:51
Syndicate
Agnico Eagle to sell approximately 5M shares to institutional investor »

Agnico Eagle Mines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

  • 28

    Apr

HUN

Huntsman

$22.89

0.24 (1.06%)

17:50
03/27/17
03/27
17:50
03/27/17
17:50
Hot Stocks
Huntsman sees Q1 adjusted EBITDA to exceed the $274M reported in 1Q16 »

Huntsman Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

SELB

Selecta Biosciences

$11.92

-0.12 (-1.00%)

, RHT

Red Hat

$82.20

-0.76 (-0.92%)

17:43
03/27/17
03/27
17:43
03/27/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SELB

Selecta Biosciences

$11.92

-0.12 (-1.00%)

RHT

Red Hat

$82.20

-0.76 (-0.92%)

SNX

SYNNEX

$118.32

1.38 (1.18%)

PSIX

Power Solutions

$6.40

0.07 (1.11%)

OCN

Ocwen

$4.89

0.08 (1.66%)

TSRO

Tesaro

$156.73

-3.27 (-2.04%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FMSA

Fairmount Santrol

$6.74

-0.08 (-1.17%)

HCLP

Hi-Crush Partners

$15.40

0.05 (0.33%)

DECK

Deckers Brands

$56.51

0.23 (0.41%)

CYRX

Cryoport

$3.75

0.2219 (6.29%)

EVH

Evolent Health

$21.25

0.4 (1.92%)

STOR

STORE Capital

$23.46

-0.25 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 04

    Apr

  • 06

    Apr

  • 12

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 30

    Jun

ADHD

Alcobra

17:41
03/27/17
03/27
17:41
03/27/17
17:41
Hot Stocks
Brosh raises stake in Alcobra to 10.9% ahead of investor meeting »

Brosh Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PSIX

Power Solutions

$6.40

0.07 (1.11%)

17:33
03/27/17
03/27
17:33
03/27/17
17:33
Hot Stocks
Weichai America to invest $60M in Power Solutions »

Power Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RADA

RADA Electronic

$1.15

-0.04 (-3.36%)

17:32
03/27/17
03/27
17:32
03/27/17
17:32
Syndicate
Breaking Syndicate news story on RADA Electronic »

RADA Electronic files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$17.15

0.34 (2.02%)

17:29
03/27/17
03/27
17:29
03/27/17
17:29
Syndicate
Breaking Syndicate news story on iShares Silver Trust »

iShares Silver Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAU

iShares Gold Trust

$12.08

0.07 (0.58%)

17:28
03/27/17
03/27
17:28
03/27/17
17:28
Syndicate
Breaking Syndicate news story on iShares Gold Trust »

iShares Gold Trust files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GABC

German American Bancorp

$44.33

-0.33 (-0.74%)

17:25
03/27/17
03/27
17:25
03/27/17
17:25
Hot Stocks
German American Bancorp announces 3-for-2 stock split »

German American Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$0.95

0.2215 (30.34%)

17:18
03/27/17
03/27
17:18
03/27/17
17:18
Hot Stocks
Staffing 360 Solutions, board reject buy-out offer from Jackson Investment Group »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$15.40

-0.24 (-1.53%)

17:16
03/27/17
03/27
17:16
03/27/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Canada Goose »

Adage Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$140.32

-0.02 (-0.01%)

, AAPL

Apple

$140.88

0.24 (0.17%)

17:14
03/27/17
03/27
17:14
03/27/17
17:14
Periodicals
Facebook hires Apple vet to lead Oculus hardware efforts, Bloomberg says »

Facebook (FB) has hired…

FB

Facebook

$140.32

-0.02 (-0.01%)

AAPL

Apple

$140.88

0.24 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

ISTR

Investar Holding

$22.15

0.1 (0.45%)

17:13
03/27/17
03/27
17:13
03/27/17
17:13
Hot Stocks
Breaking Hot Stocks news story on Investar Holding »

EJF Capital reports 6.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$23.21

0.27 (1.18%)

17:10
03/27/17
03/27
17:10
03/27/17
17:10
Hot Stocks
Breaking Hot Stocks news story on Urban Outfitters »

Harry S. Cherken, Jr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.